Delayed wound healing during therapy of cutaneous graft-versus-host disease with everolimus;Wundheilungsstörung bei kutaner graft-versus-host-disease unter therapie mit everolimus

Hautarzt

Volumn 65, Issue 6, 2014, Pages 553-555

  Brown, A ^a   Neumayer, D ^a   Rafiee Tari Z ^a   Krieg, T ^a   Eming, S A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Allogeneic stem cell transplantation; Immunosuppressive therapy; mTOR inhibitor; Skin ulcerations; Transplantation medicine

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; SKIN ULCER; WOUND HEALING IMPAIRMENT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; GRAFT VS HOST DISEASE; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS; SKIN ULCER; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84902272883     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-014-2762-y     Document Type: Article

References (16)

1. Abouelnasr A et al (2013) Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment. Biol Blood Marrow Transplant 19:12-21
2. Bootun R (2013) Effects of immunosuppressive therapy on wound healing. Int Wound J 10:98-104
3. Euvrard S et al (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329-339
4. Feldmeyer L et al (2012) Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis but impair wound healing. BJD 166:422-424
5. Javier AF et al (1997) Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J Clin Invest 99:2094-2099 (Pubitemid 27203765)
6. Jedlickova Z et al (2011) Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors. Biol Blood Marrow Transplant 17:657-663
7. Lee DF et al (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130:440-455
8. Pidala J et al (2013) Biologic markers of chronic GVHD. Bone Marrow Transplant [Epub ahead of print]
9. Skert C et al (2006) Sclerodermatous chronic graft-versus-host disease after allogenetic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 91:258-261
10. Socie G (2009) The NIH consensus criteria for chronic graft-versus-host disease: far more than just another classification. Leukemia 23:1-2
11. Squarize CH et al (2010) Accelerated wound healing by mTOR activation in genetically defined mouse models. PLoS One 5(5)
12. Travnik R et al (2011) Graft versus Host Disease (GvHD) - an update - Part 1: pathophysiology, clinical features and classification of GvHD. Hautarzt 2:139-155
13. Travnik R et al (2011) Graft versus Host Disease (GvHD) - an update - Part 2: prognosis and therapy of GvHD. Hautarzt 3:229-239
14. Weinreich J et al (2011) Rapamycin-induced impaired wound healing is associated with compromised tissue lactate accumulation and extracellular matrix remodelling. Eur Surg Res 47:39-44
15. Wolff D et al (2010) Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 16: 1611-1628
16. Wullschleger S et al (2006) TOR signaling in growth and metabolism. Cell 124:471-484 (Pubitemid 43199434)